Aligning the IVD lifecycle for regulatory, clinical, and commercial success

Bringing an IVD from concept to regulatory approval isn’t a checklist—it’s a strategic obstacle course. While a few assays glide through submission, far more are delayed—often for years—not because of technical shortcomings, but due to preventable misalignments in strategy and study design.

Seasoned regulatory leaders know: most delays aren’t the result of one major misstep. They’re the cumulative effect of smaller, avoidable issues—an imprecise intended use, overlooked regulatory touchpoints, or study protocols misaligned with final claims. By the time these gaps are discovered, teams have already invested significant time, budget, and resources. The cost: rework, submission amendments, and, in too many cases, stalled programs.

This whitepaper is written for clinical scientists, regulatory strategists, and diagnostics program leaders managing global submissions. It identifies five of the most critical—and costly—missteps in IVD study design and regulatory planning. Drawing on anonymized real-world cases from DCN Dx’s portfolio, it offers practical strategies to avoid or correct these issues before they derail progress.

Why this matters: For anyone responsible for advancing assays from bench to clinical use, these challenges are either already known—or imminent. This paper goes beyond generic best practices to address the realities of cross-functional coordination, changing global requirements (FDA, IVDR, and others), and the strategic decisions that make or break a submission.